secwatch.observer — SEC 8-K summary
======================================

Issuer:     Iterum Therapeutics plc (ITRMF)
CIK:        0001659323
Form:       8-K
Filed at:   2023-05-04T23:59:59+00:00
Accession:  0000950170-23-017662
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 3.03, 5.03, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Iterum shareholders approve capital increase but reject pre-emption opt-out
---------------------------------------------------------------------------

- Authorized share capital increased from $1.2M to $1.8M via 60M new ordinary shares effective May 3, 2023.
- Pre-emption rights opt-out proposal failed with 60.9% in favor, below required 75% supermajority.
- Beth P. Hecht and Michael W. Dunne elected as Class II directors for three-year terms expiring at 2026 AGM.
- Shareholders ratified KPMG as independent auditor for fiscal 2023 and authorized board to set remuneration.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1659323/000095017023017662/0000950170-23-017662-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1659323/000095017023017662/itrm-20230503.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-017662

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer